American Century Companies Inc. Purchases 67,325 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

American Century Companies Inc. grew its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 12.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 612,616 shares of the company’s stock after acquiring an additional 67,325 shares during the quarter. American Century Companies Inc. owned about 1.07% of Structure Therapeutics worth $16,614,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of Montreal Can raised its stake in Structure Therapeutics by 71.6% during the third quarter. Bank of Montreal Can now owns 46,502 shares of the company’s stock valued at $1,941,000 after purchasing an additional 19,408 shares in the last quarter. FMR LLC increased its holdings in shares of Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after buying an additional 383,635 shares during the last quarter. Verition Fund Management LLC raised its position in shares of Structure Therapeutics by 15.3% during the 3rd quarter. Verition Fund Management LLC now owns 16,703 shares of the company’s stock valued at $733,000 after buying an additional 2,218 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Structure Therapeutics in the 3rd quarter valued at about $3,753,000. Finally, Cinctive Capital Management LP grew its position in Structure Therapeutics by 111.0% in the third quarter. Cinctive Capital Management LP now owns 32,094 shares of the company’s stock worth $1,409,000 after acquiring an additional 16,883 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Down 12.4 %

Shares of Structure Therapeutics stock opened at $17.31 on Tuesday. Structure Therapeutics Inc. has a 52 week low of $17.24 and a 52 week high of $62.74. The company has a market capitalization of $992.61 million, a PE ratio of -23.39 and a beta of -2.37. The stock’s fifty day moving average is $23.99 and its two-hundred day moving average is $31.00.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on GPCR shares. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.